Navigating Advances in Alport Syndrome: Enhancing Diagnosis and Optimizing Outcomes

CME: 1.0

Target Audience

This activity is designed to meet the educational needs of nephrologists, ophthalmologists, audiologists, and allied healthcare professionals who during their practice may treat and/or manage patients with Alport syndrome.

Program Overview

Alport syndrome, also known as hereditary nephritis, is a rare genetic disorder characterized by progressive kidney disease and abnormalities of the inner ear and the eye, affecting 30,000 to 60,000 patients in the US alone accounting for 3% of children with chronic kidney disease (CKD) and 0.2% of adults with end stage renal disease (ESRD). Greatly underdiagnosed and misdiagnosed, the main hallmark of the disease is early hematuria with progressive decline in kidney function, ultimately resulting in kidney failure.

This activity will provide comprehensive, evidence-based strategies for the diagnosis of Alport syndrome including a review of the standards of care and management of extra-renal manifestations, including new and emerging agents in development that have the potential to improve the health and wellbeing of patients with this disorder.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ measures to improve the diagnosis of Alport Syndrome
  • Identify the standards of care for kidney disease
  • Apply strategies for treatment collaboration among HCPs to manage extra-renal manifestations
  • Interpret results from recent and ongoing trials and their practical implications on patient care

Post a comment to this article